Background The nucleotide analogue prodrug remdesivir was among the first antiviral
therapies to be tested in randomized controlled trials (RCTs) for COVID-19. We performed a
meta-analysis to understand efficacy and safety. Methods We searched PubMed, EMBASE,
Cochrane library, and ClinicalTrials. gov databases (from January 1, 2020 to November 5,
2020). We included RCTs comparing the efficacy and safety of remdesivir to control/placebo
in COVID-19. Two independent investigators abstracted data, assessed the quality of …

Background The benefits of remdesivir in the treatment of hospitalized patients with COVID-
19 remain debated with the National Institutes of Health and the World Health Organization
providing contradictory recommendations for and against use. Objectives To evaluate the
role of remdesivir for hospitalized inpatients as a function of oxygen requirements. Data
sources Beginning with our prior systematic review, we searched MEDLINE using PubMed
from 15 January 2021 through 5 May 2022. Study eligibility criteria Randomised controlled …